MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Bristol-Myers Squibb Co.

Uždarymo kaina

SektoriusSveikatos priežiūra

59.47 -2.51

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

59.23

Max

60.97

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.1B

76M

Pardavimai

442M

12B

P/E

Sektoriaus vid.

14.05

73.239

Pelnas, tenkantis vienai akcijai

1.67

Dividendų pajamingumas

4.06

Pelno marža

0.616

Darbuotojai

34,100

EBITDA

-1.9B

2.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+1.52% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

4.06%

3.06%

Kitas uždarbis

2025-04-24

Kitas dividendų mokėjimo data

2025-05-01

Kita Ex Dividend data

2025-04-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-744M

120B

Ankstesnė atidarymo kaina

61.98

Ankstesnė uždarymo kaina

59.47

Naujienos nuotaikos

By Acuity

40%

60%

138 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Bristol-Myers Squibb Co. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-03-11 10:13; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

2025-03-11 10:13; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

2025-02-06 12:13; UTC

Uždarbis

Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook

2025-03-14 09:30; UTC

Svarbiausios naujienos

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

2025-03-11 02:26; UTC

Įsigijimai, susijungimai, perėmimai

Abecma Is an Immunotherapy Indicated for Treatment of Relapsed or Refractory Multiple Myeloma >TSVT

2025-03-11 02:26; UTC

Įsigijimai, susijungimai, perėmimai

Stockholders Owning About 5.3% of 2seventy Bio Shares Have Agreed to Tender All Their Shares >TSVT

2025-03-11 02:26; UTC

Įsigijimai, susijungimai, perėmimai

2seventy Bio CEO: Rationale for Deal Clear, in Line With Focus on Unlocking Value of Abecma >TSVT

2025-03-11 02:23; UTC

Įsigijimai, susijungimai, perėmimai

2seventy Bio Stock Will No Longer Trade on Nasdaq After Closing of Deal, Expected in 2Q >TSVT

2025-03-11 02:22; UTC

Įsigijimai, susijungimai, perėmimai

2seventy Bio's Board Unanimously Recommends Stockholders Tender Shares in Offer >TSVT

2025-03-11 02:21; UTC

Įsigijimai, susijungimai, perėmimai

Bristol Myers Deal Represents 88% Premium to 2seventy Closing Price of $2.66 on March 7 >TSVT

2025-03-11 02:21; UTC

Įsigijimai, susijungimai, perėmimai

Bristol Myers to Acquire 2seventy Bio Shares at $5.00 Each in All-Cash Deal for Equity Value of About $286M >TSVT

2025-03-11 02:19; UTC

Įsigijimai, susijungimai, perėmimai

2seventy Bio Enters Into Definitive Agreement to Be Acquired by Bristol Myers Squibb

2025-02-28 12:00; UTC

Svarbiausios naujienos

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025-02-06 15:35; UTC

Uždarbis

Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD

2025-02-06 13:56; UTC

Uždarbis

Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. -- IBD

2025-02-06 13:25; UTC

Svarbiausios naujienos
Uždarbis

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

2025-02-06 12:00; UTC

Uždarbis

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

2025-02-06 11:59; UTC

Uždarbis

Bristol-Myers Squibb 4Q Gross Margin 61.0% >BMY

2025-02-06 11:59; UTC

Uždarbis

Bristol-Myers Squibb 4Q Rev $12.3B >BMY

2025-02-06 11:59; UTC

Uždarbis

Bristol-Myers Squibb 4Q Net $72M >BMY

2025-02-06 11:59; UTC

Uždarbis

Bristol-Myers Squibb 4Q EPS 4c >BMY

2025-02-06 11:59; UTC

Uždarbis

Bristol-Myers Squibb 4Q Adj EPS $1.67 >BMY

2025-02-06 11:59; UTC

Uždarbis

Bristol Myers Squibb: Expanding Existing Strategic Productivity Initiative to Include About $2B in Additional Annualized Cost Savings by the End of 2027 >BMY

2025-02-06 11:59; UTC

Uždarbis

Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.7B >BMY

2025-02-06 11:59; UTC

Uždarbis

Bristol Myers Squibb 4Q U.S. Revenue Rose 9% to $8.6B >BMY

2025-02-06 11:59; UTC

Uždarbis

Bristol Myers Squibb 4Q Legacy Portfolio Revenue $5.98B, Down 4% >BMY

2025-02-06 11:59; UTC

Uždarbis

Bristol Myers Squibb: 4Q Growth Portfolio Revenue Primarily Due to Higher Demand for Reblozyl, Breyanzi, Camzyos, Yervoy and Opdualag >BMY

2025-02-06 11:59; UTC

Uždarbis

Bristol Myers Squibb 4Q Rev $12.34B >BMY

2025-02-06 11:59; UTC

Uždarbis

Bristol Myers Squibb: 4Q Legacy Portfolio Revenue Lower Vs Yr-Ago Primarily Due to Impact of Generics on Sprycel, Revlimid, Abraxane and Pomalyst, Partially Offset by Higher Demand for Eliquis >BMY

2025-02-06 11:59; UTC

Uždarbis

Bristol Myers Squibb: 2025 Rev Outlook Reflects Near-Term Impact of Generics Across Revlimid, Pomalyst, Sprycel and Abraxane >BMY

Akcijų palyginimas

Kainos pokytis

Bristol-Myers Squibb Co. Prognozė

Kainos tikslas

By TipRanks

1.52% į viršų

12 mėnesių prognozė

Vidutinis 60.93 USD  1.52%

Aukščiausias 70 USD

Žemiausias 37 USD

Remiantis 16 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Bristol-Myers Squibb Co. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

16 ratings

5

Pirkti

10

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

59.99 / 61.34Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

138 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.